Study summary
Adding ramucirumab to chemotherapy gave long disease control in thymic carcinoma
43.8months median survival
What was tested
Ramucirumab, an antibody that blocks blood-vessel growth, with carboplatin and paclitaxel as first treatment for metastatic thymic carcinoma. No comparison group.
What they found
- Tumors shrank in 57.6% on independent review.
- Median time before the cancer grew was 18.1 months, and median survival 43.8 months.
- About half had serious side effects.
What it means
Among the best results reported in this cancer, compared with past patients.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.